Condition Directory

Lung Cancer clinical trials

Directory of U.S. ClinicalTrials.gov public records for Lung Cancer. Browse Lung Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 31, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 31, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

5916

Shown on this page

Current sort

How Lung Cancer studies are organized in the registry

The registry splits lung cancer records between non-small cell (NSCLC) and small cell (SCLC) disease, and a large share of NSCLC studies are organized around a biomarker rather than the diagnosis alone. If a mutation or marker drives your search, query it directly — it typically appears verbatim in titles. A dedicated non-small cell lung cancer page is also available in this directory.

Terms that often appear in related listings

NSCLC small cell lung cancer EGFR ALK KRAS

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 589–600 of 5,916 matching trials for Lung Cancer.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: N-Power Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Monterey, California • Dover, Delaware • Milford, Delaware + 8 more

Conditions: Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Small Cell Neuroendocrine Carcinoma
Interventions: Cabozantinib S-malate, Ipilimumab, Nivolumab; Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 45
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 35 more

Conditions: EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine
Interventions: Olaparib, Durvalumab, EKG, Tumor biopsy, CT chest, abdomen and pelvis, MRI chest, abdomen and pelvis; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatocellular Cancer, Squamous-Cell Non-Small Cell Lung Cancer
Interventions: Lenvatinib, ABBV-324; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 7 more

Conditions: Breast Cancer Stage III, HER2-positive Metastatic Breast Cancer, Unresectable Breast Carcinoma, Her2-Positive, HER2 Gene Mutation, Gastroesophageal-junction Cancer, Non Small Cell Lung Cancer, Endometrial Neoplasms, Peritoneal Cancer, Fallopian Tube Cancer, Ovarian Cancer, Urothelial Carcinoma Bladder, Solid Tumor, Adult, Gastric Cancer
Interventions: BL-M17D1; Drug
Lead sponsor: SystImmune Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • Lake Mary, Florida + 6 more

Conditions: Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
Interventions: ASP546C; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Miami, Florida + 15 more

Conditions: Solid Tumors
Interventions: Avelumab; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Sacramento, California + 20 more

Conditions: Lung Cancer, Tobacco Use
Interventions: Community health worker delivered outreach, shared decision-making, tobacco treatment, and navigation, Lay Navigator delivered outreach, shared decision-making, tobacco treatment, and navigation, Enhanced Usual Care; Behavioral · Other
Lead sponsor: Baystate Medical Center; Other
Eligibility: 50 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions: Carboplatin, Paclitaxel, Pevonedistat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 10
States / cities: Los Angeles, California • Newport Beach, California • Washington D.C., District of Columbia + 4 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II
Interventions: Durvalumab, the EORTC Core Quality of Life Questionnaire (EORTC QLQ-C30), COPD Assessment Test (CAT), Modified Medical Research Council (mMRC) dyspnea scale; Drug · Other · Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Charlotte, North Carolina • Winston-Salem, North Carolina

Conditions: Non-small Cell Lung Cancer
Interventions: Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 11
States / cities: Tampa, Florida • Baton Rouge, Louisiana • Baltimore, Maryland + 5 more

About this Lung Cancer clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Lung Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Lung Cancer.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Lung Cancer clinical trials

How Lung Cancer studies are organized in the registry

Filter and sort this condition

Live official records

An External Control Arm Study in Non-Small Cell Lung Cancer

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Avelumab Program Rollover Study

A Community Health Intervention to Improve Lung Cancer Screening Uptake in Community Health Centers

Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

About this Lung Cancer clinical trials directory page